Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| Sunitinib | Sunitinib is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit. Uses: Angiogenesis inhibitors; antineoplastic agents. Group: Pharmaceutical. CAS No. 557795-19-4. Pack Sizes: 2.5 g. Product ID: B0084-186154. Molecular formula: Custom synthesis is available. Send your inquiries for more information. |  London |
| Sunitinib-[d10] | One of the isotopic labelled form of Sunitinib, which is a receptor tyrosine kinases inhibitor. Group: Pharmaceutical. CAS No. 1126721-82-1. Pack Sizes: 25 mg. Product ID: BLP-013107. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Sunitinib Impurities | Sunitinib Impurities play a pivotal role in the pharmaceutical sector, primarily concerned with the quality control and analysis of Sunitinib, an oral tyrosine kinase inhibitor. These impurities are essential for the treatment of renal cell carcinoma and gastrointestinal stromal tumors by ensuring the drug's safety, efficacy, and stability. Group: Pharmaceutical. Pack Sizes: 1mg; 1g; 10g. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Sunitinib Impurity G HCl | One of the impurities of Sunitinib, which is a receptor tyrosine kinases inhibitor. Group: Pharmaceutical. CAS No. 1217216-61-9. Pack Sizes: 10 mg. Product ID: B2694-482813. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Sunitinib malate | Sunitinib (marketed as Sutent by Pfizer, and previously known as SU11248) is an oral, small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST) on January 26, 2006. Sunitinib was the first cancer drug simultaneously approved for two different indications. Uses: Angiogenesis inhibitors. Group: Pharmaceutical. CAS No. 341031-54-7. Pack Sizes: 1 g. Product ID: NP3249. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| DCC-2618 | DCC-2618 inhibits normal and mutant KIT kinase at the nanomol level. The targets are wt c-KIT, c-KIT mutants, PDGFR alpha, PDGFR beta, KDR and cFMS. DCC-2618 inhibits mutant KIT in GIST patient cell line (GIST T1 pKIT western Ex11 deletion) at a IC 50 of 2 nM. Deciphera's technology has identified DCC-2618 as a molecule which can be developed as second line therapy for imatinib and sunitinib resistant GIST patients with the potential to progress to frontline GIST therapy. DCC-2618 has been designed to effectively inhibit the imatinib and sunitinib-sensitive KIT juxtamembrane domain mutants (JMD) as well as secondary resistant KIT kinase-domain mutants. DCC-2618 additionally targets PDGFR alpha oncogenic mutants. Group: Pharmaceutical. CAS No. 1225278-16-9. Pack Sizes: 50 mg. Product ID: B0084-457687. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
